Antibody-Fcγ receptor-driven NOX2 activation during phagocytosis of tumor cells is suppressed by CD47, preventing CD8 T cell engagement and immunotherapeutic responses.

Antibody-dependent cellular phagocytosis (ADCP) contributes to the elimination of antibody-opsonized tumor cells and engagement of adaptive immunity. This process is inhibited by tumor-cell overexpression of CD47. Here, genome-wide CRISPR screens in macrophages identified the NADPH oxidase (NOX2 complex) and the CD47 receptor, SIRPα, as regulators of phagosome acidification. Target-cell CD47 suppressed NOX2 generation of reactive oxygen species at antibody densities that support ADCP, revealing distinct CD47-dependent thresholds for ADCP and oxidant generation. CD47 removal from the target cell delayed phagosome acidification in wild-type macrophages, but not in NOX2-deficient macrophages. Consistent with a role for this pathway in antitumor immunity, tumor-opsonizing anti-Tyrp1 therapy allowed clearance of CD47-deficient B16F10 melanoma tumors in approximately 36% of wild-type mice but failed in NOX2-deficient mice. Tumor clearance required CD8 T cells and IFNγ, but perforin was dispensable. CD4 T cell depletion markedly improved tumor clearance. These findings suggest a noncanonical role for CD8 T cells in supporting ADCP-mediated tumor control. Combining anti-Tyrp1 with a mouse-serum-albumin-IL-2 fusion (MSA-IL-2) or PD-1 blockade enabled superior clearance of CD47-deficient tumors in NOX2-deficient mice, but not wild-type mice. Rechallenge experiments distinguished primary tumor clearance from durable immunity, whereby NOX2-deficient mice treated with anti-Tyrp1 and PD-1 blockade lacked rechallenge protection despite high initial cure rates. Conversely, the addition of MSA-IL-2 supported durable protection in both wild-type and NOX2-deficient mice. These results indicate that tumor CD47 functions beyond a "don't-eat-me" signal by controlling NOX2 activity to positively and negatively regulate CD 8 T cell function. Significance CD47-SIRPα suppresses NOX2 activation, regulating a critical feedback loop between ADCP and CD8 T cell activation during tumor-opsonizing antibody therapy, suggesting new strategies for cancer immunotherapy targeting tumor surface antigens.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-20
DOI
https://doi.org/10.64898/2026.11.19.767930
Primary Topic
Phagocytosis and Immune Regulation
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Antibody-Fcγ receptor-driven NOX2 activation during phagocytosis of tumor cells is suppressed by CD47, preventing CD8 T cell engagement and immunotherapeutic responses.

Adam D. Hoppe, Stephen M. Thirdborough, Natalie W. Thiex, Seuly Akter et al.
1 links
bioRxiv (Cold Spring Harbor Laboratory)
Phagocytosis and Immune Regulation
preprint

Antibody-Fcγ receptor-driven NOX2 activation during phagocytosis of tumor cells is suppressed by CD47, preventing CD8 T cell engagement and immunotherapeutic responses.

Adam D. Hoppe, Stephen M. Thirdborough, Natalie W. Thiex, Seuly Akter, Stephen A. Beers, Mark Steven Cragg, Jason G. Kerkvliet, Jadyn Leek, Pratibha Sharma, Lauren J. Olson, Esme J.C. Fowkes, Hallie M. Kueter
preprint en

Abstract

Antibody-dependent cellular phagocytosis (ADCP) contributes to the elimination of antibody-opsonized tumor cells and engagement of adaptive immunity. This process is inhibited by tumor-cell overexpression of CD47. Here, genome-wide CRISPR screens in macrophages identified the NADPH oxidase (NOX2 complex) and the CD47 receptor, SIRPα, as regulators of phagosome acidification. Target-cell CD47 suppressed NOX2 generation of reactive oxygen species at antibody densities that support ADCP, revealing distinct CD47-dependent thresholds for ADCP and oxidant generation. CD47 removal from the target cell delayed phagosome acidification in wild-type macrophages, but not in NOX2-deficient macrophages. Consistent with a role for this pathway in antitumor immunity, tumor-opsonizing anti-Tyrp1 therapy allowed clearance of CD47-deficient B16F10 melanoma tumors in approximately 36% of wild-type mice but failed in NOX2-deficient mice. Tumor clearance required CD8 T cells and IFNγ, but perforin was dispensable. CD4 T cell depletion markedly improved tumor clearance. These findings suggest a noncanonical role for CD8 T cells in supporting ADCP-mediated tumor control. Combining anti-Tyrp1 with a mouse-serum-albumin-IL-2 fusion (MSA-IL-2) or PD-1 blockade enabled superior clearance of CD47-deficient tumors in NOX2-deficient mice, but not wild-type mice. Rechallenge experiments distinguished primary tumor clearance from durable immunity, whereby NOX2-deficient mice treated with anti-Tyrp1 and PD-1 blockade lacked rechallenge protection despite high initial cure rates. Conversely, the addition of MSA-IL-2 supported durable protection in both wild-type and NOX2-deficient mice. These results indicate that tumor CD47 functions beyond a "don't-eat-me" signal by controlling NOX2 activity to positively and negatively regulate CD 8 T cell function. Significance CD47-SIRPα suppresses NOX2 activation, regulating a critical feedback loop between ADCP and CD8 T cell activation during tumor-opsonizing antibody therapy, suggesting new strategies for cancer immunotherapy targeting tumor surface antigens.

bioRxiv (Cold Spring Harbor Laboratory)
South Dakota State University (US), University of Southampton (GB)
South Dakota State University, Cancer Research UK, National Institutes of Health, National Institute of Allergy and Infectious Diseases
Good health and well-being
Phagocytosis and Immune Regulation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon